Fort Myers, Fla.-based NeoGenomics Inc. launched an underwritten public offering of about $150 million of its common shares.

Underwriters will have a 30-day option to buy up to an additional $22.5 million of shares at the public offering price.

The company, which focuses on cancer genetics testing, plans to use net proceeds for general corporate purposes, and may use a portion of the funds to acquire or invest in complementary businesses and technologies.

Morgan Stanley, SVB Leerink and William Blair are acting as the underwriters' representatives and book-running managers. Cantor Fitzgerald, Craig-Hallum Capital Group and Needham & Co. are serving as co-managers.